Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial Meeting Abstract


Authors: Jhaveri, K. L.; Makker, V.; Wang, X. V.; Chen, A. P.; Flaherty, K.; Conley, B. A.; O'Dwyer, P. J.; Williams, P. M.; Hamilton, S. R.; Harris, L.; McShane, L.; Rubinstein, L.; Gray, R. J.; Li, S. L.; Mitchell, E. P.; Patton, D.; Moscow, J.; Zwiebel, J. A.; Arteaga, C. L.; Luoh, S. W.
Abstract Title: Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 6s
Language: English
ACCESSION: WOS:000442916000002
DOI: 10.1200/JCO.2018.36.15_suppl.100
PROVIDER: wos
Notes: Meeting Abstract: 100 -- Source: Wos
Altmetric Score
MSK Authors
  1. Vicky Makker
    71 Makker
  2. Komal Lachhman Jhaveri
    39 Jhaveri